Socioeconomic barriers to healthcare cost-sharing in the Czech Republic: limited awareness and resistance. [PDF]
Health Econ RevHodač J +5 more
europepmc +1 more source
Excess Mortality as the Primary Mediator of COVID-19's Impact on Life Expectancy in Europe: A Multilevel Longitudinal Analysis of Regional Disparities. [PDF]
Medicina (Kaunas)Țarcă V +8 more
europepmc +1 more source
Financial Assistance Policy, Hospital Charity Care, and Medical Debt in Collections.
JAMA Netw OpenSantos T +3 more
europepmc +1 more source
The moderating role of the case-mix index in the relationship between medical staff allocation and average cost per inpatient visit. [PDF]
Front Public HealthXiong C, Xia Y, Xu S, Xiao J.
europepmc +1 more source
Global Economic and Social Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review (2020-2024). [PDF]
Int J Chron Obstruct Pulmon DisGutiérrez-Villegas C +6 more
europepmc +1 more source
Restaurant Advertising Expenditure Patterns in US Counties by Race, Ethnicity, and Income. [PDF]
J Urban HealthStephenson BJK +3 more
europepmc +1 more source
Prayer, politics, and policy related to age-adjusted cancer, heart disease, infant mortality, and COVID-19 death Rates, U.S. states 2018-2021. [PDF]
PLoS OneRobertson LS.
europepmc +1 more source
A Simple Game–theoretic Framework for studying R&D expenditures and R&D Cooperation
, 2001 openaire +1 more source
R&D Expenditure, Patent, and the Uncertainty of Future Earnings
R&D Expenditure, Patent, and the Uncertainty of Future Earningsopenaire
CAPITALIZING R&D EXPENDITURES [PDF]
Macroeconomic Dynamics, 2010 The next international version of the System of National Accounts will recommend that R&D (Research and Development) expenditures be capitalized instead of being immediately expensed as in the present System of National Accounts 1993. An R&D project creates a new technology, which in principle does not depreciate like a reproducible asset.
Diewert, Erwin, Huang, Ning
openaire +1 more source